🇺🇸 FDA
Patent

US 10822429

Etanercept formulations exhibiting marked reduction in sub-visible particles

granted A61KA61K2039/505A61K38/1793

Quick answer

US patent 10822429 (Etanercept formulations exhibiting marked reduction in sub-visible particles) held by Coherus BioSciences, Inc. expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Coherus BioSciences, Inc.
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K38/1793, A61K47/02, A61K47/10